 This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 2 Week 0, subjects meeting all entry criteria will be randomized to one of two treatment sequences: placebo or POM3 for the first 6 week phase followed by the study product they did not receive during the first phase POM3 or placebo for the second 6 weeks. There will be a 2-week washout period between treatment phases. 